Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669899 · ClinicalTrials.gov registry record · Phase 1
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
A Phase 1 study of Cancer, sponsored by Jounce Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT04669899: Completed Phase 1 study of Cancer, sponsored by Jounce Therapeutics.
NCT04669899 is a Phase 1 study of Cancer that has completed, run by Jounce Therapeutics. The registered enrollment target is 190 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04669899, a Phase 1 study of Cancer, has completed, sponsored by Jounce Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).
Conditions Studied
Interventions
- DRUG JTX-8064
- DRUG pimivalimab
Study Locations (20)
California
- City of Hope - Duarte
- California Cancer Associates for Research & Excellence, Inc. - La Jolla
- University of California, San Diego - La Jolla
- Cedars Sinai - Los Angeles
- UC Irvine Medical Center - Orange
- University of California, Davis - Sacramento
Florida
- University of Florida - Gainesville
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
- Adventist Health System/Sunbelt, Inc. - Orlando
- Tampa General Hospital - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Clinical Research Center - Tucson
Illinois
- University of Chicago - Chicago
- Cancer Care Center of Decatur - Decatur
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas Medical Sciences - Little Rock
Connecticut
- Yale University - New Haven
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 1 |
What the finished NCT04669899 record still lists
NCT04669899 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which JTX-8064 is the first listed.
NCT04669899 names 20 study sites across 10 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04669899 about?
NCT04669899 is a clinical study titled "Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors". JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).
What is the current status of trial NCT04669899?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2021-01-12. Estimated completion is 2023-11-28.
What conditions does trial NCT04669899 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT04669899?
The interventions under investigation include: JTX-8064 (DRUG), pimivalimab (DRUG).
Who is sponsoring clinical trial NCT04669899?
This trial is sponsored by Jounce Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669899 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04669899's enrollment target sits among peer trials
190 241st of 615 higher than 375 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI